vTv Therapeutics Inc.

NASDAQ:VTVT

Biotechnology

Healthcare
$16.23 +1.47%

+$0.50 today

Market cap
$64.17M
Beta
0.27
P/E (TTM)
128.7
EPS (TTM)
$0.27
52W Low $14.00High $44.00

Volume 0.02M

Average 0.05M

VTVT Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

vTv Therapeutics Inc.NASDAQ: VTVT

Net Margin · Q1 FY2026 · quarter ended Mar 2026

Net margin at 65.5%

Net margin was 65.5% in Q1 FY2026. On a trailing-twelve-month basis it was 6.1%, up 109941.4 pp year over year.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
65.5%— QoQ
Last fiscal yearDec 2025
—— YoY
LTMMar 2026
6.1%+109941.4 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Net Margin history

Percent of revenue · from the income statement

Latest · FY2024
-1815.3%
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How VTVT compares with its peers on the latest reported figures

  • VTVT's LTM Mar 2026 net margin of 6.1% is the 2nd highest of the 5 companies compared; the peer median is -617.5%.
  • Its year-over-year change of +109941.4 pp is the highest of 3, against a peer median of -15224.0 pp.
VTVT Competitors Peer median
Net Margin for VTVT and competitors
Company Period LTM level YoY 3-year change
FBIOFortress Biotech, Inc.LTM Mar 2026193.1% +264.4 pp+125.1 pp
VTVTvTv Therapeutics Inc.LTM Mar 20266.1% +109941.4 pp—
HOWLWerewolf Therapeutics, Inc.LTM Jun 2026-164.8% ——
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026-1070.3% ——
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-18297.5% -30712.4 pp—
SPRBSpruce Biosciences, Inc.FY2025— ——
INKTMiNK Therapeutics, Inc.FY2025— ——
GANXGain Therapeutics, Inc.FY2025— ——
OSTXOS Therapies IncorporatedFY2025— ——
Peer median (excluding VTVT) -617.5%-15224.0 pp+125.1 pp

Competitors are the stored peer set for VTVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.01M2.02M01.02M0
Cost of Revenue00000
Gross Profit4.01M2.02M01.02M0
Gross Margin100.0%100.0%—100.0%—
Research & Development13.32M12.36M13.6M11.55M17.86M
Selling, General & Admin12.34M12.2M11.91M13.65M14.95M
Operating Expenses25.67M24.56M25.5M25.2M32.81M
Depreciation & Amortization89K92K90K89K16K
EBITDA(17.52M)(24.77M)(25.86M)(22.52M)(31.06M)
EBITDA Margin-437.3%-1227.3%—-2214.0%—
Operating Income(21.66M)(22.54M)(25.5M)(24.18M)(32.81M)
Operating Margin-540.9%-1116.9%—-2377.6%—
Interest Income1K352K472K1.57M1.87M
Interest Expense12K15K13K06K
Other Income / Expenses4.05M(2.33M)(464K)1.58M1.73M
Income Before Tax(17.62M)(24.87M)(25.97M)(22.61M)(31.08M)
Pre-Tax Margin-439.9%-1232.6%—-2222.7%—
Income Tax Expense115K200K0100K0
Net Income(12.99M)(19.16M)(20.25M)(18.46M)(26.97M)
Net Margin-324.3%-949.7%—-1815.3%—
EPS (Basic)(8.29)(9.98)(9.71)(3.20)(3.20)
EPS (Diluted)(8.29)(9.98)(9.71)(3.20)(3.20)
Weighted Avg Shares1.57M1.92M2.08M5.77M8.42M
Weighted Avg Shares (Diluted)1.57M1.92M2.08M5.77M8.42M

vTv Therapeutics Inc.

NASDAQ:VTVT

Intrinsic Alpha fair value

Locked

Current Price

$16.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.